TY - JOUR T1 - Reduced risk of placental parasitaemia associated with complement fixation on <em>Plasmodium falciparum</em> by antibodies among pregnant women JF - medRxiv DO - 10.1101/2021.06.02.21258254 SP - 2021.06.02.21258254 AU - D. Herbert Opi AU - Michelle J. Boyle AU - Alistair McLean AU - Linda Reiling AU - Jo-Anne Chan AU - Danielle I. Stanisic AU - Alice Ura AU - Ivo Mueller AU - Freya J. Fowkes AU - Stephen J. Rogerson AU - James G. Beeson Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/05/2021.06.02.21258254.abstract N2 - Background The pathogenesis of malaria in pregnancy (MiP) involves accumulation of P. falciparum-infected red blood cells (pRBCs) in the placenta, contributing to poor pregnancy outcomes. Parasite accumulation is primarily mediated by P. falciparum erythrocyte membrane 1 (PfEMP1). Magnitude of IgG to pRBCs has been associated with reduced risk of MiP in some studies, but associations have been inconsistent. Further, antibody effector mechanisms are poorly understood, and the role of antibody complement interactions is unknown.Methods Studying a longitudinal cohort of pregnant women (n=302) from a malaria-endemic province in Papua New Guinea (PNG), we measured the ability of antibodies to fix and activate complement using placental binding pRBCs and PfEMP1 recombinant domains. We determined antibody-mediated complement inhibition of pRBC binding to the placental receptor, chondroitin sulfate A (CSA) and associations with protection against placental parasitaemia.Results Some women acquired antibodies that effectively promoted complement fixation on placental-binding pRBCs. Complement fixation correlated with IgG1 and IgG3 antibodies, which dominated the response. There was, however, limited evidence for membrane attack complex activity or pRBC lysis or killing. Importantly, a higher magnitude of complement fixing antibodies was prospectively associated with reduced odds of placental infection at delivery. Using genetically-modified P. falciparum and recombinant PfEMP1 domains, we found that complement-fixing antibodies primarily targeted a specific variant of PfEMP1 (known as VAR2CSA). Furthermore, complement enhanced the ability of antibodies to inhibit pRBC binding to CSA, which was primarily mediated by complement C1q protein.Conclusion These findings provide new insights into mechanisms mediating immunity to MiP and reveal potential new strategies for developing malaria vaccines that harness antibody-complement interactions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Health and Medical Research Council (Project grant 575534 and Program Grant 1092789 to J.G.B. and S.J.R; Investigator Grant 1173046 and Research Fellowship 1077626 to J.G.B). Burnet Institute is supported by NHMRC Independent Research Institutes Infrastructure Support Scheme and the Victorian State Government Operational Infrastructure Support. JGB, SJR, IM, FFJF, HO, LR, MJB and JAC are members of the NHMRC Australian Centre for Research Excellence in Malaria Elimination.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approved by IRB of Alfred Health and Walter and Eliza Hall Institute Australia, and Medical Research Advisory Council Papua New GuineaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. ER -